Skip to main content
PMC home page
Oncology Letters logoLink to Oncology Letters
. 2018 Nov 23;17(2):1851–1858. doi: 10.3892/ol.2018.9753

Pemetrexed exerts anticancer effects by inducing G0/G1-phase cell cycle arrest and activating the NOXA/Mcl-1 axis in human esophageal squamous cell carcinoma cells

Xinying Li 1, Hongxia Song 2, Feng Kong 3, Yanxia Guo 3, Yuan Chen 3, Lu Zhang 3, Dongfang Gao 3, Xiaofei Zhao 1,3,✉, Han Zhang 1,✉
PMCID: PMC6341790  PMID: 30675247

Abstract

Esophageal squamous cell carcinoma (ESCC) is a dominant histological subtype of esophageal cancer with notably high incidence and mortality rates. Pemetrexed is a clinical antifolate therapeutic agent with anticancer properties. The present study aimed to understand whether pemetrexed is able to exert anticancer effects on ESCC cells, and to determine the underlying molecular mechanism. ESCC cells were treated with pemetrexed and cell survival was assessed with MTT assays. The cell cycle and apoptosis were evaluated using flow cytometry analysis, and proteins were detected using western blotting. It was demonstrated that pemetrexed inhibited cell survival and induced G0/G1 cell cycle arrest and apoptosis in human ESCC cells. Furthermore, the results demonstrated that the phorbol-12-myristate-13-acetate-induced protein 1/induced myeloid leukemia cell differentiation protein Mcl-1 axis is involved in intrinsic apoptosis induced by pemetrexed. The protein expression of endoplasmic reticulum stress markers inositol-requiring enzyme 1α, binding immunoglobulin protein and CCAAT-enhancer-binding protein homologous protein were upregulated following treatment with pemetrexed. These results suggest that pemetrexed may induce an endoplasmic reticulum stress response while activating intrinsic apoptosis. The present study provided important mechanistic insights into potential cancer treatments involving pemetrexed and enhanced the understanding of human ESCC.

Keywords: esophageal squamous cell carcinoma, pemetrexed, cell cycle arrest, apoptosis, endoplasmic reticulum stress

Introduction

Esophageal cancer, which consists of two principal subtypes, adenocarcinoma and esophageal squamous cell carcinoma (ESCC), is the sixth leading cause of cancer-associated mortality worldwide (1). Compared with adenocarcinoma, ESCC is more common in East Asia, and ~50% of ESCC cases occur in China (2–4). Due to the rapid progression and high malignancy, the prognosis of patients with ESCC remains poor (5).

Chemotherapy is the most common treatment for cancer (1). Unfortunately, the majority of chemotherapeutic drugs have a limited effect on ESCC due to side effects and drug resistance (6). Thus, there is an urgent need to develop safe, efficacious agents with limited harmful effects for the treatment of ESCC.

Pemetrexed is a novel multi-targeted antifolate that targets a number of crucial enzymes involved in folate metabolism (7). Recent studies have reported that pemetrexed is also able to act as an antitumor drug, and its cytotoxicity has been demonstrated in advanced non-small cell lung cancer and malignant pleural mesothelioma (8,9). However, the effects of pemetrexed on human esophageal cancer and the possible mechanisms of such effects remain to be elucidated. Determining whether pemetrexed exhibits anticancer effects on ESCC cells and understanding the underlying molecular mechanism are important for developing better chemotherapeutics for ESCC.

Cell cycle arrest and apoptosis induced by cytotoxic agents are critical in cancer treatment (10,11). The intrinsic mitochondrial pathway is an important signaling cascade associated with apoptosis. Members of the apoptosis regulator Bcl-2 (Bcl-2) family serve crucial roles in the regulation of apoptotic processes in various cancer cells (12). Phorbol-12-myristate-13-acetate-induced protein 1 (NOXA), a crucial pro-apoptotic protein in the Bcl-2 family, has been reported to be involved in chemotherapeutic agent-induced apoptosis (13). NOXA is able to interact with the anti-apoptotic Bcl-2 protein induced myeloid leukemia cell differentiation protein Mcl-1 (Mcl-1), interfering with the polymerization of apoptosis regulator BAX and Bcl-2 homologous antagonist/killer to trigger the mitochondrial apoptosis pathway (14). The combination of NOXA and Mcl-1 may also facilitate the proteasomal degradation of Mcl-1 and thereby strengthen intrinsic apoptosis (15).

Previous studies have demonstrated that the activation of the intrinsic mitochondrial apoptosis pathway is associated with persistent endoplasmic reticulum (ER) stress (16). Once inositol-requiring enzyme 1α (IRE1α) and other ER sensors are released from binding immunoglobulin protein (Bip), downstream effectors, including CCAAT-enhancer-binding protein homologous protein (CHOP) may trigger pro-apoptotic signals by targeting numerous apoptotic genes (17,18). However, whether the intrinsic mitochondrial apoptosis pathway and ER stress are active following treatment with pemetrexed in human ESCC cells remains unknown.

The present study investigated whether pemetrexed exerted anticancer effects on ESCC cells. The role of the cell cycle and the NOXA/Mcl-1 axis in the regulation of this effect was also studied. The present study revealed the therapeutic potential of pemetrexed for ESCC and enriched the understanding of this cancer type.

Materials and methods

Antibodies and reagents

Pemetrexed (cat no. CDS024404), was purchased from Sigma-Aldrich; Merck KGaA (Darmstadt, Germany), and was dissolved in dimethyl sulfoxide (DMSO; Sigma-Aldrich; Merck KGaA) at a concentration of 10 mmol/l (19). The stock solutions were stored at −20°C and diluted to the desired concentrations with growth medium prior to use. All the antibodies were previously described (13). Antibodies targeting caspase (casp)8 (cat no. 9746; 1:1,000 dilution), casp9 (cat no. 9502; 1:1,000 dilution), poly(ADP-ribose) polymerase (PARP; cat no. 9542; 1:1,000 dilution), IRE1α (cat no. 3294; 1:2,000 dilution) and Bip (cat no. 3183; 1:1,000 dilution) were obtained from Cell Signaling Technology, Inc. (Danvers, MA, USA). Antibodies targeting casp3 (cat no. NB100-56708; 1:1,000 dilution) and NOXA (cat no. OP180; 1:500 dilution) were purchased from Imgenex (Novus Biologicals, LLC, Littleton, CO, USA) and Calbiochem; Merck KGaA, respectively. Anti-actin antibody (cat no. A5441; 1:20,000 dilution) was obtained from Sigma-Aldrich; Merck KGaA. Antibodies against CHOP (cat no. sc-7351; 1:100 dilution) and Mcl-1 (cat no. sc-12756; 1:1,000 dilution) were purchased from Santa Cruz Biotechnology, Inc. (Dallas, TX, USA).

Cell lines and cell culture

The human ESCC cell lines Eca-109 and EC9706 were obtained from the American Type Culture Collection (Manassas, VA, USA) and were grown in monolayer cultures at 37°C in a humidified atmosphere consisting of 5% CO2 and 95% air. The cells were cultured with RPMI-1640 medium containing 5% fetal bovine serum (both Gibco; Thermo Fisher Scientific Inc., Waltham, MA, USA).

Cell treatment and MTT assay

A total of 7×104 cells were seeded in 96-well microtiter plates and treated with 0, 0.625, 1.25, 2.5, 5 and 10 µM pemetrexed on the 2nd day. Following culturing with chemotherapeutics for 24, 36 or 48 h, cells were subjected to the MTT assay. Each sample was incubated with 20 µl (5 mg/ml) MTT (Sigma-Aldrich; Merck KGaA) at 37°C for 4 h. Following incubation, the solution was discarded and 100 µl DMSO was added. Cell viability was determined by measuring the absorbance at 495 nm using an ELISA Multiskan reader (Thermo Fisher Scientific, Inc.).

Cell cycle analysis

The cell cycle was evaluated through DNA flow cytometry analysis. Overall, 2×105 cells were seeded in six-well plates and treated with different concentrations of pemetrexed (0, 2.5, 5 and 10 µM) for 24 h. Following treatment, cells were harvested and washed twice with ice-cold PBS and fixed in 70% ethanol at −20°C overnight. Prior to analysis, cells were washed with ice-cold PBS and incubated at 4°C with 5 µl propidium iodide (PI; 100 µg/ml) and 5 µl RNase (50 µg/ml; both Beijing Solarbio Science & Technology Co., Ltd., Beijing, China) for 30 min in the dark. The samples were analyzed using a FACScan flow cytometer and the BD FACSuite™ flow cytometry software (version 1.0.5; both BD Biosciences, San Jose, CA, USA). Data analysis was performed using FlowJo software (version 7.2.2; Tree Star, Inc. San Carlos, CA, USA) (13).

Apoptosis analysis

Apoptosis was evaluated according to a previously described protocol (13). The Annexin V-fluorescein isothiocyanate (FITC)/PI apoptosis detection kit was purchased from Nanjing Biobox Biotech (Nanjing, China). Following treatment with different concentrations of pemetrexed (0, 2.5, 5 and 10 µM) for 36 h, 2×106 cells were harvested, washed with pre-chilled PBS and resuspended in 500 µl binding buffer. A total of 5 µl each of Annexin V-FITC and PI were added to each sample, and the samples were incubated for 10 min in the dark at room temperature. Analysis was performed by flow cytometry with the aforementioned flow cytometer and software.

Western blot analysis

Whole-cell protein lysates were prepared and analyzed by western blotting according to a previously described protocol (13). Cells were treated with different concentrations of pemetrexed (0, 2.5, 5 and 10 µM) for 36 h, harvested and rinsed with pre-chilled PBS. Cell extracts were lysed and centrifuged at 12,000 × g for 15 min at 4°C, and the protein concentration was determined via the bicinchoninic acid assay. Whole-cell protein lysates (40 µg) were separated by SDS-PAGE on a 12% gel and transferred to Hybond-enhanced chemiluminescence (ECL) membranes via electroblotting. Following blocking with 5% skimmed milk at room temperature for 1 h, the proteins were first probed with the appropriate primary antibodies at 4°C overnight followed by secondary goat anti-rabbit/mouse monoclonal antibodies (cat nos. SA00001-1 and SA00001-2; 1:8,000 dilution; ProteinTech Group, Inc., Chicago, IL, USA). Antibody binding was detected using an ECL system (EMD Millipore, Billerica, MA, USA), according to the manufacturer's protocol. The expression levels of the proteins were quantified using ImageJ software (version 1.6.0_24; National Institute of Health, Bethesda, MD, USA).

Statistical analysis

SPSS statistical software (version 20.0; IBM Corp., Armonk, NY, USA) was used for all statistical analyses. The data obtained represent the mean ± standard deviation of at least three independent assays performed in duplicate or triplicate. A one-way analysis of variance followed by a Least Significant Difference post hoc test was performed for testing for all data. P<0.05 was considered to indicate a statistically significant difference.

Results

Pemetrexed inhibits the survival of human ESCC cells

The cytotoxicity of pemetrexed in ESCC cells was analyzed by treating Eca-109 and EC9706 cells with various concentrations of pemetrexed for various times and performing an MTT assay. The results demonstrated that pemetrexed may induce survival inhibition in human ESCC cells. When the exposure time was prolonged, the inhibitory effect was enhanced in Eca-109 and EC9706 cells (Fig. 1). These results suggested that pemetrexed may effectively suppress the survival of human ESCC cells.

Figure 1.

Figure 1.

Open in a new tab

Pemetrexed inhibits the survival of human esophageal squamous cell carcinoma cells. (A) Eca-109 and (B) EC9706 cells were treated with 0, 0.625, 1.25, 2.5, 5 or 10 µM pemetrexed and incubated for the indicated times. Cell survival was estimated using the MTT assay. The survival rate of each drug concentration was compared with that of the control group and analyzed using SPSS software. All data are presented as the mean ± standard deviation. ***P<0.001. PEM, pemetrexed.

Pemetrexed induces G0/G1 cell cycle arrest in ESCC cells

To determine the molecular mechanism by which pemetrexed induced survival inhibition in human ESCC cells, the ability of the agent to induce cell cycle arrest was analyzed by DNA flow cytometry analysis. The results demonstrated that cell cycle arrest was induced in a concentration-dependent manner; over the range of drug treatments (0–10 µM), the frequency of G1 cells increased from 57.63 to 80.34% in Eca-109 cells (Fig. 2A). Similar results were reported in EC9706 cells, in which the frequency of G1 cells increased from 45.94 to 65.05% (Fig. 2B). These results indicated that exposure to pemetrexed may trigger G0/G1 cell cycle arrest in human ESCC cells.

Figure 2.

Figure 2.

Open in a new tab

Pemetrexed induces G0/G1 cell cycle arrest in human esophageal squamous cell carcinoma cells. (A) Eca-109 and (B) EC9706 cells were treated with 0, 2.5, 5 or 10 µM pemetrexed and incubated for 24 h. Following treatment, the cells were harvested for cell cycle assays. The frequency of G1-phase cells was quantified using FlowJo software and analyzed using SPSS. All data are presented as the mean ± standard deviation. **P<0.01, ***P<0.001. PI, propidium iodide; PEM, pemetrexed; RMS, root mean square.

Pemetrexed induces apoptosis in human ESCC cells

The present study also sought to determine whether apoptosis was involved in the inhibition of survival induced by pemetrexed. Therefore, an apoptosis assay was performed via Annexin V/PI staining. The resulting data revealed that pemetrexed induced apoptosis in a concentration-dependent manner in Eca-109 and EC9706 cells (Fig. 3). When treated with pemetrexed (0–10 µM), the frequency of apoptosis was increased from 4.317 to 32.43% in Eca-109 cells and 9.795 to 43.48% in EC9706 cells. Furthermore, the expression levels of apoptotic proteins were detected via western blot analysis. The data demonstrated that pemetrexed induced cleavage and activation of the apoptotic proteins casp8, casp9, casp3 and PARP in a concentration-dependent manner in human ESCC cells (Figs. 4 and 5). These results indicated that exposure to pemetrexed may trigger apoptosis. In conclusion, pemetrexed triggers G0/G1 cell cycle arrest and apoptosis in human ESCC cells.

Figure 3.

Figure 3.

Open in a new tab

Pemetrexed induces apoptosis in human esophageal squamous cell carcinoma cells. (A) Eca-109 and (B) EC9706 cells were treated with 0, 2.5, 5 or 10 µM pemetrexed and incubated for 36 h. Following treatment, the cells were harvested for apoptosis assays. The percentage of apoptotic cells was quantified using FlowJo software and analyzed using SPSS software. All data are presented as the mean ± standard deviation. *P<0.05, **P<0.01, ***P<0.001. Q1: (Annexin V− FITC)−/PI+, necrotic cells. Q2: (Annexin V−FITC)+/PI+, late apoptotic cells. Q3: (Annexin V− FITC)+/PI−, early apoptotic cells. Q4: (Annexin V− FITC)−/PI−, normal control cells. PI, propidium iodide; FITC, fluorescein isothiocyanate; PEM, pemetrexed.

Figure 4.

Figure 4.

Open in a new tab

Pemetrexed activates a caspase cascade reaction in human esophageal squamous cell carcinoma cells. (A) Eca-109 and (B) EC9706 cells were treated with 0, 2.5, 5 or 10 µM pemetrexed and incubated for 36 h. Following treatment, whole-cell protein lysates (40 µg) were examined via western blot analysis. FL, full-length; CF, cleaved form; PEM, pemetrexed; PARP, poly(ADP-ribose) polymerase; Casp, caspase.

Figure 5.

Figure 5.

Open in a new tab

Pemetrexed activates casp9 and PARP in human esophageal squamous cell carcinoma cells. (A) Eca-109 and (B) EC9706 cells were treated with 0, 2.5, 5 or 10 µM pemetrexed and incubated for 36 h. Following treatment, the protein levels of the cells were measured via western blot analysis. All data are presented as the mean ± standard deviation. *P<0.05, **P<0.01, ***P<0.001. Casp, caspase; PARP, poly(ADP-ribose) polymerase; NS, not significant.

Involvement of the NOXA/Mcl-1 axis in pemetrexed-induced apoptosis

The NOXA/Mcl-1 axis has been reported to be involved in chemotherapeutically-induced apoptosis in numerous types of tumor cells (12,13). To characterize the molecular mechanism of pemetrexed-induced apoptosis in human ESCC cells, the expression levels of proteins following treatment with pemetrexed were analyzed. Western blot analysis revealed that the expression of NOXA was upregulated in a concentration-dependent manner following treatment with pemetrexed. By contrast, the expression levels of Mcl-1 decreased (Fig. 6A and B). These results indicated that the NOXA/Mcl-1 axis may be involved in pemetrexed-induced apoptosis in human ESCC cells. The expression level of Bcl-2, which is another member of the Bcl-2 family, was also detected and the western blotting results demonstrated that Bcl-2 was downregulated following treatment with pemetrexed (Fig. 6C and D). In summary, pemetrexed may induce mitochondrial apoptosis in human ESCC cells.

Figure 6.

Figure 6.

Open in a new tab

Involvement of the NOXA/MCL-1 axis in pemetrexed-induced apoptosis. (A and C) Eca-109 and (B and D) EC9706 cells were treated with 0, 2.5, 5 or 10 µM pemetrexed and incubated for 36 h. Following treatment, NOXA and Mcl-1 expression was quantified via western blot analysis. All data are presented as the mean ± standard deviation. *P<0.05, **P<0.01, ***P<0.001. PEM, pemetrexed; NOXA, phorbol-12-myristate-13-acetate-induced protein 1; Mcl-1, induced myeloid leukemia cell differentiation protein Mcl-1; Bcl-2, apoptosis regulator Bcl-2; NS, not significant.

Pemetrexed triggers ER stress in human ESCC cells

The ER response has been reported to be activated by chemotherapeutics while inducing apoptosis in cancer cells (12,20). To determine whether pemetrexed triggers ER stress in human ESCC cells, a number of relevant proteins in the ER stress pathway were examined. The results illustrated that the marker proteins IRE1α, Bip and CHOP were upregulated in a concentration-dependent manner following treatment with pemetrexed (Fig. 7). These results indicated that pemetrexed may trigger ER stress in human ESCC cells.

Figure 7.

Figure 7.

Open in a new tab

Pemetrexed triggers endoplasmic reticulum stress in human esophageal squamous cell carcinoma cells. (A) Eca-109 and (B) EC9706 cells were treated with 0, 2.5, 5 or 10 µM pemetrexed and incubated for 36 h. Following treatment, the protein expression of IRE1α, Bip and CHOP was quantified via western blot analysis. All data are presented as the mean ± standard deviation, *P<0.05, **P<0.01, ***P<0.001. NS, not significant; PEM, pemetrexed; IRE1α, inositol-requiring enzyme 1α; CHOP, CCAAT-enhancer-binding protein homologous protein; Bip, binding immunoglobulin protein.

Discussion

Esophageal cancer is the third leading cause of cancer-associated mortality in China (21). The incidence and mortality rates of esophageal cancer in China have increased in recent years (21,22). ESCC is the predominant histological subtype of esophageal cancer. Due to its high malignancy and the inadequate efficacy of conventional therapy, ESCC frequently has an unfavorable prognosis (23,24). Thus, the development of effective novel agents and treatments is of the utmost importance.

Pemetrexed is a clinically available multi-target antifolate cytotoxic agent (19). It is able to inhibit the synthesis of purine and pyrimidine by blocking dihydrofolate reductase, thymidylate synthase and glycinamide ribonucleotide formyltransferase (25). Recently, pemetrexed has been reported to exhibit antitumor effects in various solid tumors (19,25). The present study aimed to determine whether pemetrexed was able to exert anticancer effects in ESCC and to elucidate the underlying molecular mechanism.

In the present study, the cytotoxicity of pemetrexed against ESCC cells was analyzed, and it was reported that pemetrexed displayed a time-dependent inhibitory effect on the survival of ESCC cells. Subsequently, it was demonstrated that pemetrexed induced G0/G1-phase cell cycle arrest and apoptosis in a concentration-dependent manner in human ESCC cells. These results indicated that pemetrexed may exert anticancer effects by inducing G0/G1-phase cell cycle arrest and apoptosis in human ESCC cells. It has also been demonstrated that pemetrexed combined with cisplatin displays an effective synergistic effect in a wide variety of solid tumors (12,26,27). However, how this combination may exert a beneficial synergistic effect in human ESCC cells, and the underlying molecular mechanism, requires further research.

The results of the present study revealed that necrosis was also increased following treatment with pemetrexed. Cell death occurs via necrosis in addition to apoptosis. Research has reported that cell apoptosis and necrosis may be led by ER stress and mitochondrial membrane permeability (28,29). In the present study, persistent ER stress and increasing mitochondrial membrane permeability may be involved in the induction of necrosis. The molecular mechanism and effect of necrosis in pemetrexed-induced survival inhibition requires further investigation.

To understand the underlying molecular mechanism by which pemetrexed induces apoptosis in human ESCC cells, the expression levels of apoptosis-associated proteins were analyzed. NOXA and Mcl-1 are key proteins in intrinsic mitochondrial apoptosis. It was reported that the expression levels of the pro-apoptotic protein NOXA was upregulated in a concentration-dependent manner following treatment with pemetrexed, while the expression levels of the anti-apoptotic protein Mcl-1 decreased. The results indicated that pemetrexed may induce intrinsic mitochondrial apoptosis via the NOXA/Mcl-1 axis in human ESCC cells. The expression levels of Bcl-2 were also measured and the western blotting results demonstrated that Bcl-2 was downregulated following treatment with pemetrexed. In summary, pemetrexed may induce mitochondrial apoptosis in human ESCC cells. In addition to intrinsic mitochondrial apoptosis, extrinsic death receptor apoptosis is another key apoptotic signaling pathway. However, further research is required to determine whether pemetrexed induces extrinsic death receptor apoptosis in human ESCC cells.

A number of chemotherapeutics activate an ER response while inducing apoptosis in cancer cells (12,20). To determine whether pemetrexed triggers ER stress in human ESCC cells, a number of relevant proteins in the ER stress pathway were investigated. The results demonstrated that the marker proteins IRE1α, Bip and CHOP were upregulated in a concentration-dependent manner following treatment with pemetrexed, which indicates that pemetrexed triggers ER stress in human ESCC cells. Cyclic AMP-dependent transcription factor ATF-3 (ATF3) is also a key protein marker of ER stress (30). ATF3 has been reported to act as a suppressor of CHOP in a number of cancer types, whereas it may promote the expression of CHOP in others (31,32). Previous studies have reported that the expression of ATF3 is downregulated in certain ESCCs, and this decreased expression is negatively correlated with a poor prognosis in vivo, and with cell growth and invasion in vitro (33,34). However, further research is required to determine whether ATF3 is involved in pemetrexed-induced ER stress in human ESCC cells.

In conclusion, the results of the present study demonstrated that pemetrexed was able to inhibit cell survival and induce G0/G1-phase cell cycle arrest and apoptosis in human ESCC cells. The NOXA/Mcl-1 axis may be involved in intrinsic apoptosis induced by pemetrexed. Furthermore, pemetrexed induced an ER stress response while activating apoptosis. The present study provided important mechanistic insights into pemetrexed as a potential cancer treatment and enhanced the current understanding of human ESCC.

Acknowledgements

The authors would like to thank the staff of the Central Research Laboratory of the Second Hospital of Shandong University (Jinan, China) for their technical assistance and support.

Funding

The present study was supported by the Shandong Natural Science Foundation (grant no. ZR2016HP43) and the key research and development plan of Shandong Province (grant no. 2015GSF118037).

Availability of data and materials

All data generated or analyzed during this study are included in this article.

Authors' contributions

XZ and HZ participated in every step of the design project and in specific experiments. XL also participated in the design of this study and most of the experiments, and was the writer of this manuscript. HS helped in the experiments and modified the language of the manuscript. FK participated in the quantification of proteins and provided advice for the revision of the manuscript. YG cultured the cells for this study. YC, LZ and DG performed the statistical analysis. All authors read and approved the manuscript and agree to be accountable for all aspects of the research in ensuring that the accuracy or integrity of any part of the work are appropriately investigated and resolved.

Ethics approval and consent to participate

Not applicable.

Patient consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

References

  • 1.Lagergren J, Lagergren P. Recent developments in esophageal adenocarcinoma. CA Cancer J Clin. 2013;63:232–248. doi: 10.3322/caac.21185. [DOI] [PubMed] [Google Scholar]
  • 2.Yang P, Zhao J, Hou L, Yang L, Wu K, Zhang L. Vitamin E succinate induces apoptosis via the PI3K/AKT signaling pathways in EC109 esophageal cancer cells. Mol Med Rep. 2016;14:1531–1537. doi: 10.3892/mmr.2016.5445. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Brown LM, Devesa SS, Chow WH. Incidence of adenocarcinoma of the esophagus among white Americans by sex, stage, and age. J Natl Cancer Inst. 2008;100:1184–1187. doi: 10.1093/jnci/djn211. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.He J, Zhou M, Chen X, Yue D, Yang L, Qin G, Zhang Z, Gao Q, Wang D, Zhang C, et al. Inhibition of SALL4 reduces tumorigenicity involving epithelial-mesenchymal transition via Wnt/β-catenin pathway in esophageal squamous cell carcinoma. J Exp Clin Cancer Res. 2016;35:98. doi: 10.1186/s13046-016-0378-z. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90. doi: 10.3322/caac.20107. [DOI] [PubMed] [Google Scholar]
  • 6.Mariette C, Robb WB, Piessen G, Adenis A. Neoadjuvant chemoradiation in esophageal cancer. Lancet Oncol. 2015;16:1008–1009. doi: 10.1016/S1470-2045(15)00127-8. [DOI] [PubMed] [Google Scholar]
  • 7.Seiwert TY, Connell PP, Mauer AM, Hoffman PC, George CM, Szeto L, Salgia R, Posther KE, Nguyen B, Haraf DJ, Vokes EE. A phase I study of pemetrexed, carboplatin, and concurrent radiotherapy in patients with locally advanced or metastatic non-small cell lung or esophageal cancer. Clin Cancer Res. 2007;13:515–522. doi: 10.1158/1078-0432.CCR-06-1058. [DOI] [PubMed] [Google Scholar]
  • 8.Raizer JJ, Rademaker A, Evens AM, Rice L, Schwartz M, Chandler JP, Getch CC, Tellez C, Grimm SA. Pemetrexed in the treatment of relapsed/refractory primary central nervous system lymphoma. Cancer. 2012;118:3743–3748. doi: 10.1002/cncr.26709. [DOI] [PubMed] [Google Scholar]
  • 9.Zhang JP, Lee EQ, Nayak L, Doherty L, Kesari S, Muzikansky A, Norden AD, Chen H, Wen PY, Drappatz J. Retrospective study of pemetrexed as salvage therapy for central nervous system lymphoma. J Neurooncol. 2013;115:71–77. doi: 10.1007/s11060-013-1196-1. [DOI] [PubMed] [Google Scholar]
  • 10.Feng Y, Yang Y, Fan C, Di S, Hu W, Jiang S, Li T, Ma Z, Chao D, Feng X, et al. Pterostilbene inhibits the growth of human esophageal cancer cells by regulating endoplasmic reticulum stress. Cell Physiol Biochem. 2016;38:1226–1244. doi: 10.1159/000443071. [DOI] [PubMed] [Google Scholar]
  • 11.Guo YX, Lin ZM, Wang MJ, Dong YW, Niu HM, Young CY, Lou HX, Yuan HQ. Jungermannenone A and B induce ROS- and cell cycle-dependent apoptosis in prostate cancer cells in vitro. Acta Pharmacol Sin. 2016;37:814–824. doi: 10.1038/aps.2016.26. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Zhao X, Kong F, Wang L, Zhang H. c-FLIP and the NOXA/Mcl-1 axis participate in the synergistic effect of pemetrexed plus cisplatin in human choroidal melanoma cells. PLoS One. 2017;12:e0184135. doi: 10.1371/journal.pone.0184135. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Zhao X, Liu X, Su L. Parthenolide induces apoptosis via TNFRSF10B and PMAIP1 pathways in human lung cancer cells. J Exp Clin Cancer Res. 2014;33:3. doi: 10.1186/1756-9966-33-3. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Liu X, Lv Z, Zou J, Liu X, Ma J, Wang J, Sa N, Jing P, Xu W. Afatinib down-regulates MCL-1 expression through the PERK-eIF2alpha-ATF4 axis and leads to apoptosis in head and neck squamous cell carcinoma. Am J Cancer Res. 2016;6:1708–1719. [PMC free article] [PubMed] [Google Scholar]
  • 15.Hauck P, Chao BH, Litz J, Krystal GW. Alterations in the Noxa/Mcl-1 axis determine sensitivity of small cell lung cancer to the BH3 mimetic ABT-737. Mol Cancer Ther. 2009;8:883–892. doi: 10.1158/1535-7163.MCT-08-1118. [DOI] [PubMed] [Google Scholar]
  • 16.Wang H, Yang Y, Chen H, Dan J, Cheng J, Guo S, Sun X, Wang W, Ai Y, Li S, et al. The predominant pathway of apoptosis in THP-1 macrophage-derived foam cells induced by 5-aminolevulinic acid-mediated sonodynamic therapy is the mitochondria-caspase pathway despite the participation of endoplasmic reticulum stress. Cell Physiol Biochem. 2014;33:1789–1801. doi: 10.1159/000362958. [DOI] [PubMed] [Google Scholar]
  • 17.Lee JH, Kwon EJ, Kim DH. Calumenin has a role in the alleviation of ER stress in neonatal rat cardiomyocytes. Biochem Biophys Res Commun. 2013;439:327–332. doi: 10.1016/j.bbrc.2013.08.087. [DOI] [PubMed] [Google Scholar]
  • 18.Chow SE, Kao CH, Liu YT, Cheng ML, Yang YW, Huang YK, Hsu CC, Wang JS. Resveratrol induced ER expansion and ER caspase-mediated apoptosis in human nasopharyngeal carcinoma cells. Apoptosis. 2014;19:527–541. doi: 10.1007/s10495-013-0945-0. [DOI] [PubMed] [Google Scholar]
  • 19.Su L, Liu G, Hao X, Zhong N, Zhong D, Liu X, Singhal S. Death receptor 5 and cellular FLICE-inhibitory protein regulate pemetrexed-induced apoptosis in human lung cancer cells. Eur J Cancer. 2011;47:2471–2478. doi: 10.1016/j.ejca.2011.06.003. [DOI] [PubMed] [Google Scholar]
  • 20.Qin L, Wang Z, Tao L, Wang Y. ER stress negatively regulates AKT/TSC/mTOR pathway to enhance autophagy. Autophagy. 2010;6:239–247. doi: 10.4161/auto.6.2.11062. [DOI] [PubMed] [Google Scholar]
  • 21.Zeng H, Zheng R, Zhang S, Zuo T, Xia C, Zou X, Chen W. Esophageal cancer statistics in China, 2011: Estimates based on 177 cancer registries. Thorac Cancer. 2016;7:232–237. doi: 10.1111/1759-7714.12322. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, Jemal A, Yu XQ, He J. Cancer statistics in China, 2015. CA Cancer J Clin. 2016;66:115–132. doi: 10.3322/caac.21338. [DOI] [PubMed] [Google Scholar]
  • 23.Quanjun D, Qingyu Z, Qiliang Z, Liqun X, Jinmei C, Ziquan L, Shike H. Effect and mechanism of PAR-2 on the proliferation of esophageal cancer cells. Eur Rev Med Pharmacol Sci. 2016;20:4688–4696. [PubMed] [Google Scholar]
  • 24.Ma YC, Ke Y, Zi X, Zhao F, Yuan L, Zhu YL, Fan XX, Zhao NM, Li QY, Qin YH, Liu HM. Induction of the mitochondria-mediated apoptosis in human esophageal cancer cells by DS2, a newly synthetic diterpenoid analog, is regulated by Bax and caused by generation of reactive oxygen species. Oncotarget. 2016;7:86211–86224. doi: 10.18632/oncotarget.13367. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25.Sun Y, Wang Y, Han S, Xing B, Li H, Zhu Y, Zhou S, Wang X, Xu J, Tao R. Efficacy and safety of pemetrexed on recurrent primary central nervous system lymphomas in China: A prospective study. Onco Targets Ther. 2017;10:2595–2600. doi: 10.2147/OTT.S134684. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26.Bolukbas S, Manegold C, Eberlein M, Bergmann T, Fisseler-Eckhoff A, Schirren J. Survival after trimodality therapy for malignant pleural mesothelioma: Radical Pleurectomy, chemotherapy with Cisplatin/Pemetrexed and radiotherapy. Lung Cancer. 2011;71:75–81. doi: 10.1016/j.lungcan.2009.08.019. [DOI] [PubMed] [Google Scholar]
  • 27.Yang JC, Hirsh V, Schuler M, Yamamoto N, O'Byrne KJ, Mok TS, Zazulina V, Shahidi M, Lungershausen J, Massey D, et al. Symptom control and quality of life in LUX-Lung 3: A phase III study of afatinib or cisplatin/pemetrexed in patients with advanced lung adenocarcinoma with EGFR mutations. J Clin Oncol. 2013;31:3342–3350. doi: 10.1200/JCO.2012.46.1764. [DOI] [PubMed] [Google Scholar]
  • 28.Wang H, Liu Z, Gou Y, Qin Y, Xu Y, Liu J, Wu JZ. Apoptosis and necrosis induced by novel realgar quantum dots in human endometrial cancer cells via endoplasmic reticulum stress signaling pathway. Int J Nanomedicine. 2015;10:5505–5512. doi: 10.2147/IJN.S83838. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29.Arakawa S, Nakanomyo I, Kudo-Sakamoto Y, Akazawa H, Komuro I, Shimizu S. Identification of a novel compound that inhibits both mitochondria-mediated necrosis and apoptosis. Biochem Biophys Res Commun. 2015;467:1006–1011. doi: 10.1016/j.bbrc.2015.10.022. [DOI] [PubMed] [Google Scholar]
  • 30.Xu L, Su L, Liu X. PKCδ regulates death receptor 5 expression induced by PS-341 through ATF4-ATF3/CHOP axis in human lung cancer cells. Mol Cancer Ther. 2012;11:2174–2182. doi: 10.1158/1535-7163.MCT-12-0602. [DOI] [PubMed] [Google Scholar]
  • 31.Wolfgang CD, Chen BP, Martindale JL, Holbrook NJ, Hai T. Gadd153/Chop10, a potential target gene of the transcriptional repressor ATF3. Mol Cell Biol. 1997;17:6700–6707. doi: 10.1128/MCB.17.11.6700. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32.Liu G, Su L, Hao X, Zhong N, Zhong D, Singhal S, Liu X. Salermide up-regulates death receptor 5 expression through the ATF4-ATF3-CHOP axis and leads to apoptosis in human cancer cells. J Cell Mol Med. 2012;16:1618–1628. doi: 10.1111/j.1582-4934.2011.01401.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33.Tan H, Zhang H, Xie J, Chen B, Wen C, Guo X, Zhao Q, Wu Z, Shen J, Wu J, et al. A novel staging model to classify esophageal squamous cell carcinoma patients in China. Br J Cancer. 2014;110:2109–2115. doi: 10.1038/bjc.2014.101. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 34.Xie JJ, Xie YM, Chen B, Pan F, Guo JC, Zhao Q, Shen JH, Wu ZY, Wu JY, Xu LY, Li EM. ATF3 functions as a novel tumor suppressor with prognostic significance in esophageal squamous cell carcinoma. Oncotarget. 2014;5:8569–8582. doi: 10.18632/oncotarget.2322. [DOI] [PMC free article] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Data Availability Statement

All data generated or analyzed during this study are included in this article.

Articles from Oncology Letters are provided here courtesy of Spandidos Publications

RESOURCES